Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04477525
Other study ID # 2020-11082
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date June 22, 2021
Est. completion date June 2022

Study information

Verified date June 2021
Source Montefiore Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a pilot study to assess the effectiveness of erector spinae (ESP) nerve blocks for postoperative pain control following bariatric surgery. Currently, there are mainly case series/pilot studies describing the use of ESP nerve blocks for postoperative pain control in abdominal procedures; of these only one uses this treatment modality for bariatric procedures. The population undergoing bariatric surgery poses specific challenges to postoperative pain management. They often have comorbid obstructive sleep apnea, which puts them at greater risk for ventilatory depression when treated with parenteral opioids. This risk can be reduced with regional techniques. The ESP nerve blocks provide visceral and somatic pain coverage as opposed to the more commonplace transversus abdominis plane nerve block which only provides somatic coverage. This means that the ESP nerve blocks will cover incisional pain as well as the discomfort associated with the pain from the procedure itself. This study intends to build on current knowledge by proving that the use of ESP in the post-operative are providing a significant reduction in pain scores as well as reducing the need for parenteral opioids. Thus, decreasing the risk of postoperative ventilatory complications. In preparation for this study, three pilot studies were reviewed. The studies assessed the usefulness of ESP nerve blocks on patients undergoing abdominal surgery. Single-shot bilateral ESP blocks were performed in the first two studies. One of the studies, patients undergoing ventral hernia repair and the other for patients undergoing bariatric surgery. The third pilot study used bilateral ESP blocks followed by a continuous infusion on one patient undergoing an open prostatectomy with bladder reconstruction. All the ESP blocks were placed preoperatively at the T7 transverse process. In the studies using a single shot technique 20-30 ml of ropivacaine 0.5% was used. For the continuous ESP catheter an initial bolus of bupivacaine 0.25% 10 mls followed by continuous infusion rate of 6 ml/hr bilaterally. All showed a significant reduction numerical rating scale (NRS) as a primary outcome. The secondary outcome of reduced 24-hour parenteral opioid consumption was also achieved by all three studies.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2022
Est. primary completion date June 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age range 21 - 70. - ASA II: A patient with mild systemic disease-ASA III: A patient with severe systemic disease - Patients included are those immediately postoperative from bariatric surgery who have an NSR pain score >5 Exclusion Criteria: - Patients excluded are those who are ASA IV or greater, refuse nerve block intervention, - Diagnosis of any coagulopathy disorder, - Allergy to local anesthetics, - Have active infection over proposed injection sites. - Patients with ASA >III was excluded due to overall health concerns of poorly controlled chronic disease.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Ultrasound Guided Erector Spinae Plane (ESP) Nerve Block
The planned intervention is a bilateral erector spinae nerve block for patients undergoing bariatric surgery. This intervention will be performed in the PACU for patients with an NRS pain score >5. All eligible candidates who have consented for this study will be present in the PACU, have all standard ASA monitoring placed. The patient will then be placed in a sitting position. The patient will then be prepped with chlorhexidine in the thoracic region and draped in a sterile fashion. The ultrasound will be brought in over the patient and the T7 Transverse Processes (TP) will be identified. An echogenic needle will be placed under direct ultrasound guidance on the TP. Then, 20 cc of 0.25% bupivacaine will be injected.
Drug:
Bupivacaine Injection
20 cc of 0.25% bupivacaine will be injected

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Montefiore Medical Center

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of reduction of opiod usage after ESP Block This study will evaluate the role of ESP blocks in reducing 24-hour opioid requirements after bariatric surgery, specifically looking into 30% or more reduction in opioid usage ( morphine equivalence) in the 24 hours. 24 hours
Secondary Number of patients who experience an adverse events Up to 3 days
Secondary Pain scores (self reported) assessed by the NRS rating scale Pain scores will be collected every 30 mins in the PACU and at 24 and 48 hours during the hospital stay. NRS pain scale=0 no pain to 10 Worst pain imaginable Every 30 min while in the post-anesthesia care unit (PACU); at 24 and 48 hours during hospital stay
See also
  Status Clinical Trial Phase
Completed NCT03305666 - Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Phase 4
Completed NCT01200524 - A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Posttraumatic Neuralgia.. Phase 2
Not yet recruiting NCT06313294 - Postoperative Follow-up Via Text Messages Automated Versus Telephone in Patients With Continuous Regional Anesthesia N/A
Recruiting NCT04917796 - The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy) Phase 3
Completed NCT02225054 - The Effect of Dexmedetomidine on Brachial Plexus Block for Shoulder Surgery Phase 2
Completed NCT00654940 - A Study To Assess The Ability Of A Crossover Study Design To Detect The Efficacy Of Pregabalin In Post-Traumatic Neuropathic Pain Patients Phase 1
Completed NCT05313217 - Spine Position and Neural Sensitivity N/A
Completed NCT01954199 - The Effectiveness of Neurodynamic Techniques in Patients With Nerve-Related Leg Pain N/A
Completed NCT00599768 - Development and Validation for Taiwan Version ID Pain Questionnaire (ID Pain-T) and DN4 Questionnaire.
Active, not recruiting NCT03596489 - Objective Assessment of Sensory Nerve Fiber Sensitivity
Completed NCT00475904 - A Comparison of EpiCeptâ„¢ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN) Phase 2
Completed NCT02927951 - The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy Phase 3
Completed NCT03121976 - A Comparison of US and Evoked Motor Response-guided Placement of Continuous Femoral Nerve Block Following TKA N/A
Completed NCT03160937 - Neurodynamic Mobilization and Foam Rolling N/A
Recruiting NCT06402448 - Prevalence of Muscle and Nerve and Joint Pain
Completed NCT04688814 - SEQ Block for Perioperative Analgesia in Acetabular Surgery Phase 3
Completed NCT05289427 - Triple Injection Peri-sartorius (TIPS) Block N/A